REGENERON PHARMACEUTICALS INC has a total of 23 patent applications. It increased the IP activity by 0.0%. Its first patent ever was published in 2007. It filed its patents most often in Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and medical technology are ONCOLMMUNE INC, KS BIOMEDIX LTD and YANTAI RONGCHANG BIOTECHNOLOGIES CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 23 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Medical technology | |
#4 | Agriculture | |
#5 | Measurement | |
#6 | Organic fine chemistry | |
#7 | Machines |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Peptides | |
#3 | Therapeutic chemical compounds | |
#4 | Animal care | |
#5 | Microorganisms | |
#6 | Medical purpose containers | |
#7 | Analysing materials | |
#8 | Unspecified technologies | |
#9 | Sugars | |
#10 | Object sterilising |
# | Name | Total Patents |
---|---|---|
#1 | Murphy Andrew J | 5 |
#2 | Macdonald Lynn | 4 |
#3 | Stevens Sean | 3 |
#4 | Thurston Gavin | 3 |
#5 | Gurer Cagan | 2 |
#6 | Papadopoulos Nicholas J | 2 |
#7 | Pordy Robert C | 2 |
#8 | Voronina Vera | 2 |
#9 | Martin Joel H | 2 |
#10 | Sasiela William J | 2 |
Publication | Filing date | Title |
---|---|---|
AU2017341067A1 | Room temperature stable lyophilized protein | |
AU2017321682A1 | Methods for preventing or treating allergy by administering an IL-4R antagonist | |
AU2016289480A1 | Multispecific antigen-binding molecules and uses thereof | |
AU2016243527A1 | Maytansinoid derivatives, conjugates thereof, and methods of use | |
AU2012216653A1 | High affinity human antibodies to human nerve growth factor |